These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 1530684

  • 1. Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction.
    Kinoshita H, Ohishi N, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 May; 42(5):682-6. PubMed ID: 1530684
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 Feb; 42(2):174-8. PubMed ID: 1610430
    [Abstract] [Full Text] [Related]

  • 3. Distribution of recombinant human erythropoietin following multiple intravenous administration and effects of age on the distribution in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 Apr; 42(4):579-84. PubMed ID: 1642686
    [Abstract] [Full Text] [Related]

  • 4. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1991 Sep; 41(9):1004-7. PubMed ID: 1796912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
    Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):520-7. PubMed ID: 9353365
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats.
    Kato M, Okano K, Sakamoto Y, Miura K, Uchimura T, Saito K.
    Arzneimittelforschung; 2001 Jan; 51(1):91-5. PubMed ID: 11215332
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
    Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C.
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1205-10. PubMed ID: 8968342
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of erythropoietin in genetically anemic mice.
    Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    Drug Metab Dispos; 1998 Feb; 26(2):126-31. PubMed ID: 9456298
    [Abstract] [Full Text] [Related]

  • 12. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat.
    Tanaka H, Tokiwa T.
    Cancer Res; 1990 Oct 15; 50(20):6615-9. PubMed ID: 1698539
    [Abstract] [Full Text] [Related]

  • 13. Biological characterization of recombinant human erythropoietin.
    Krumwieh D, Arnold I, Seiler FR.
    Behring Inst Mitt; 1988 Aug 15; (83):193-201. PubMed ID: 3240225
    [Abstract] [Full Text] [Related]

  • 14. [Effects of partial nephrectomy on the pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (SNB-5001) in rats].
    Masunaga H, Takahira R, Kohsaka K, Sawai T.
    Nihon Yakurigaku Zasshi; 1992 Apr 15; 99(4):205-11. PubMed ID: 1607130
    [Abstract] [Full Text] [Related]

  • 15. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin.
    Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S.
    Blood; 1995 Dec 01; 86(11):4097-104. PubMed ID: 7492766
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy.
    Ferraiolo BL, McCabe J, Hollenbach S, Hultgren B, Pitti R, Wilking H.
    Drug Metab Dispos; 1989 Dec 01; 17(4):369-72. PubMed ID: 2571474
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A, Audran M, Bressolle F, Jaussaud P, Gareau R.
    Biopharm Drug Dispos; 1996 Dec 01; 17(9):805-15. PubMed ID: 8968532
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of erythropoietin in intact and anephric dogs.
    Fu JS, Lertora JJ, Brookins J, Rice JC, Fisher JW.
    J Lab Clin Med; 1988 Jun 01; 111(6):669-76. PubMed ID: 3373111
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
    Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G.
    Toxicol Appl Pharmacol; 1996 Jan 01; 136(1):75-8. PubMed ID: 8560482
    [Abstract] [Full Text] [Related]

  • 20. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
    Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA.
    J Pharmacol Exp Ther; 2001 Aug 01; 298(2):820-4. PubMed ID: 11454947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.